Enzix Duo (enalapril maleatee, indapamide) forte tablets 20 mg. №30 + coated tablets 2.5 mg. №15


Manufacturer: Serbia

Arterial hypertension.



Enzix Duo Composition
1 tablet of enalapril maleate (larger tablet) contains enalapril maleate 20 mg;

excipients: lactose monohydrate, heavy magnesium carbonate, gelatin, crospovidone, magnesium stearate;

1 film-coated tablet of indapamide (smaller tablet) contains indapamide 2.5 mg;

Excipients: lactose monohydrate, povidone K 30, crospovidone, magnesium stearate, sodium lauryl sulfate, talc, methylhydroxypropylcellulose, macrogol-6000, titanium dioxide (E 171).

Enzix Duo Release form
Combi pack: 10 tablets of enalapril maleate 20 mg (larger tablets) and 5 coated tablets, indapamide 2.5 mg (smaller tablet), in a blister; 3 blisters in a cardboard pack.

Enzix Duo Dosage form
Tablets. Coated tablets.

Enalapril maleate: round biconvex white tablets with a risk on one side.

Indapamide: round biconvex, film-coated tablets, white.
Active substance
Indapamide, ENALAPRIL



Enzix® Duo Forte contains two separate drugs in one package: angiotensin-converting inhibitor enzyme (ACE) enalapril | and diuretic | cost | indapamide |.


Enalapril maleate is an enalapril salt of maleic acid, a derivative of a compound of two amino acids – L-alanine and L-proline. Angiotensin-I-converting enzyme (ACE) is a peptidyl-peptidase, which acts as a catalyst for the conversion of angiotensin-I into a substance that increases blood pressure – angiotensin-II. After absorption, enalapril is hydrolyzed to form enalaprilat, which acts as an ACE inhibitor. Slowing of ACE results in a decrease in plasma angiotensin-II concentrations, which in turn leads to a decrease in plasma renin activity (due to the elimination of negative feedback with renin secretion) and to a decrease in aldosterone secretion.

ACE is identical to kinase-II. Thus, enalapril may also block the decrease in the concentration of bradykinin, a strong peptide vasodepressor. Nevertheless, the role that this circumstance may play in the therapeutic effect of enalapril remains open to study.

Because the mechanism by which enalapril lowers blood pressure is considered to be primary suppression of the renin-angiotensin-aldosterone system, enalapril is an antihypertensive drug even in the treatment of patients with hypertension with low renin levels.

Administration of enalapril to patients with hypertension results in a decrease in both blood pressure in both supine and standing positions, without a significant increase in heart rate.

Symptomatic translational or orthostatic hypotension is uncommon. In some patients, the development of an optimal reduction in blood pressure may require several weeks of therapy. Abrupt and abrupt discontinuation of enalapril was not associated with a rapid increase in blood pressure.

Arterial hypertension.


Hypersensitivity to enalapril, to any excipient or any other ACE inhibitor.

A history of angioedema associated with the use of ACE inhibitors.

– Hereditary or idiopathic angioedema.

Do not use Enzix® Duo Forte with drugs containing aliskiren in patients with diabetes mellitus or with impaired renal function (CFR <60 ml / min / 1.73 m2).

Pregnant women or women who are planning to become pregnant (see “Use during pregnancy or lactation”).


Hypersensitivity to the drug, other sulfonamide derivatives or to other components of the drug; anuria; hypokalemia, severe hepatic (including encephalopathy) and / or renal failure; acute violation of cerebral circulation; simultaneous use with drugs that prolong the QT interval; pregnancy; lactation period; children under 18 years of age (efficacy and safety have not been established.